Database of Chemical Substances the Potential Biomarkers of Diseases with the Meaning in Noninvasive Diagnostics

O. V. Saik ; M. P. Moshkin ; M. N. Baldin ; V. M. Groyznov ; V. A. Kozlov ; S. N. Samorokov ; P. S. Demenkov ; V. A. Ivanisenko ; N. A. Kolchanov

Matematičeskaâ biologiâ i bioinformatika, Tome 6 (2011) no. 2, pp. 250-263.

Résumé

There is a potential use of volatile biomarkers for noninvasive diagnostics in medicine. Creating a common information resource based on the integrated data from different sources of chemical compounds with the potential diagnostic meaning facilitates the planning of experiments on noninvasive diagnostics. The database containing information on potential biomarkers of diseases at the level of metabolites, enzymes, transcription factors that allows planning the experiments on noninvasive diagnostics of diseases was developed. Using database ProMeDiA on the example of aspergillosis infection caused by Aspergillus fumigatus, was undertaken the analysis of volatile compounds involved in the reactions regulated by human enzymes, associated with aspergillosis, and by A. fumigatus enzymes. The potential volatile biomarkers of aspergillosis infection were proposed. On the example of metabolism changes in rheumatoid arthritis the possibility of using database ProMeDiA for metabolic networks reconstruction, which allows identifying potential biomarkers of diseases, was demonstrated.

Bibliographie

[1] Corradi M., Mutti A., “Exhaled breath analysis: from occupational to respiratory medicine”, Acta Biomed, 76 (2005), 20–29

[2] Phillips M., Cataneo R.N., Ditkoff B.A., “Volatile markers of breast cancer in the breath”, Breast J., 9 (2003), 184–191 | DOI

[3] Pabst F., Miekisch W., Fuchs P., Kischkel S., Schubert J.K., “Monitoring of oxidative and metabolic stress during cardiac surgery by means of breath biomarkers: an observational study”, J. Cardiothorac Surg., 2 (2007), 37–44 | DOI

[4] Phillips M., Herrera J., Krishnan S., Zain M., Greenberg J., Cataneo R.N., “Variation in volatile organic compounds in the breath of normal humans”, Journal of Chromatography B., 729 (1999), 75–88 | DOI

[5] Gordon S.M., Szidon J.P., Krotoszynski B.K., Gibbons R.D., O'Neill H.J., “Volatile organic compounds in exhaled air from patients with lung cancer”, Clin. Chem., 31 (1985), 1278–1282

[6] Phillips M., Gleeson K., Hughes J.M., Greenberg J., Cataneo R.N., Baker L., McVay W.P., “Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study”, Lancet, 353 (1999), 1930–1933 | DOI

[7] Ligor M., Ligor T., Bajtarevic A., Ager C., Pienz M., Klieber M., Denz H., Fiegl M., Hilbe W., Weiss W., Lukas P., Jamnig H., Hackl M., Buszewski B., Miekisch W., Schubert J., Amann A., “Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry”, Clin. Chem. Lab. Med., 47:5 (2009), 550–560 | DOI

[8] Novak B.J., Blake D.R., Meinardi S., Rowland F.S., Pontello A., Cooper D.M., Galassetti P.R., “Exhaled methyl nitrate as a noninvasive marker of hyperglycemia in type 1 diabetes”, Proc. Natl. Acad. Sci. USA, 104:40 (2007), 15613–15618 | DOI

[9] Probert C.S., Jones P.R., Ratcliffe N.M., “A novel method for rapidly diagnosing the causes of diarrhea”, Gut, 53:1 (2004), 58–61 | DOI

[10] Tangerman A., Meuwese-Arends M.T., Jansen J.B., “Cause and composition of foetor hepaticus”, Lancet, 343 (1994), 483–490 | DOI

[11] Van den Velde S., Nevens F., Van Hee P., van Steenberghe D., Quirynen M., “GC-MS analysis of breath odor compounds in liver patients”, Journal of Chromatography B., 875 (2008), 344–348 | DOI

[12] Braden B., Lembcke B., Kuker W., Caspary W.F., “13C-breath tests: current state of the art and future directions”, Dig. Liver Dis., 39 (2007), 795–805 | DOI

[13] Chen X., Xu F., Wang Y., Pan Y., Lu D., Wang P., Ying K., Chen E., Zhang W., “A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis”, Cancer, 110:4 (2007), 835–844 | DOI

[14] Poli D., Carbognani P., Corradi M., Goldoni M., Acampa O., Balbi B., Bianchi L., Rusca M., Mutti A., “Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study”, Respir. Res., 14 (2005), 6–71

[15] Abaffy T., Duncan R., Riemer D.D., Tietje O., Elgart G., Milikowski C., DeFazio R.A., “Differential Volatile Signatures from Skin, Naevi and Melanoma: A Novel Approach to Detect a Pathological Process”, PLoS One, 5:11 (2010), 13813–13825 | DOI

[16] Qin T., Liu H., Song Q., Song G., Wang H., Pan Y., Xiong F., Gu K., Sun G., Chen Z., “The screening of volatile markers for hepatocellular carcinoma”, Cancer. Epidemiol. Biomarkers Prev., 19 (2010), 2247–2253 | DOI

[17] Liu C., Feng S., van Heemst J., McAdam K.G., “New insights into the formation of volatile compounds in mainstream cigarette smoke”, Anal. Bioanal. Chem., 396:5 (2010), 1817–1830 | DOI

[18] Filipiak W., Sponring A., Filipiak A., Ager C., Schubert J., Miekisch W., Amann A., Troppmair J., “TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro”, Cancer Epidemiol. Biomarkers Prev., 19:1 (2010), 182–195 | DOI

[19] Claudio G., Calder P.C., “Effects of Fat and Fatty Acid intake on inflammatory and immune responses: A critical review”, Ann. Nutr. Metab., 55 (2009), 123–139 | DOI

[20] Tkacova R., “Systemic Inflammation in Chronic Obstructive Pulmonary Disease: May Adipose Tissue Play a Role?”, Review of the Literature and Future Perspectives, Mediators of Inflammation, 2010 (2010), 585989–586000 | DOI

[21] Drager L.F., Jun J.C., Polotsky V.Y., “Metabolic consequences of intermittent hypoxia: Relevance to obstructive sleep apnea”, Best Practice Research Clinical Endocrinology Metabolism, 24 (2010), 843–851 | DOI

[22] Fernández-Riejos P., Najib S., Santos-Alvarez J., Martín-Romero C., Pérez-Pérez A., González-Yanes C., Sánchez-Margalet V., “Role of Leptin in the Activation of Immune Cells”, Mediators of Inflammation, 2010 (2010), 568343–568351 | DOI

[23] Yoshino T., Kusunoki N., Tanaka N., Kaneko K., Kusunoki Y., Endo H., Hasunuma T., Kawai S., “Elevated serum levels of resistin, leptin, and adiponectin are associated with C-reactive protein and also other clinical conditions in rheumatoid arthritis”, Intern. Med., 50:4 (2011), 269–275 | DOI | MR

[24] Andreelli F., Jacquier D., Troy S., “Molecular aspects of insulin therapy in critically ill patients”, Curr. Opin. Clin. Nutr. Metab. Care, 9:2 (2006), 124–130 | DOI

[25] Suryaprabha P., Das U.N., Ramesh G., Kumar K.V., Kumar G.S., “Reactive oxygen species, lipid peroxides and essential fatty acids in patients with rheumatoid arthritis and systemic lupus erythematosus”, Prostaglandins Leukot. Essent. Fatty Acids, 43:4 (1991), 251–255 | DOI

[26] Jira W., Spiteller G., “Dramatic increase of linoleic acid peroxidation products by aging, atherosclerosis, and rheumatoid arthritis”, Adv. Exp. Med. Biol., 469 (1999), 479–483 | DOI

[27] Calder P.C., “Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients”, Braz. J. Med. Biol. Res., 36:4 (2003), 433–446 | DOI

[28] Zhao X., Imig J.D., “Kidney CYP450 enzymes: biological actions beyond drug metabolism”, Curr. Drug. Metab., 4:1 (2003), 73–84 | DOI

[29] Pompeia C., Lima T., Curi R., “Arachidonic acid cytotoxicity: can arachidonic acid be a physiological mediator of cell death?”, Cell Biochem. Funct., 21:2 (2003), 97–104 | DOI

[30] Kanadaşi M., Cayli M., Demirtaş M., Inal T., Demir M., Koç M., Avkaroǧullari M., Dönmez Y., Usal A., Alhan C.C., San M., “The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol”, Heart Vessels, 21:5 (2006), 291–297 | DOI

[31] Chae J.S., Kim O.Y., Paik J.K., Kang R., Seo W.J., Jeong T.S., Sweeney G., Lee S.H., Lee J.H., “Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome”, Atherosclerosis, 218:2 (2011), 499–506 | DOI | MR

[32] Saggini A., Anogeianaki A., Maccauro G., Tete S., Salini V., Caraffa A., Conti F., Fulcheri M., Galzio R., Shaik-Dasthagirisaheb Y.B., “Cholesterol, cytokines and diseases”, Int. J. Immunopathol. Pharmacol., 24:3 (2011), 567–581

[33] Koc H., King J., Teschl G., Unterkofler K., Teschl S., Mochalski P., Hinterhuber H., Amann A., “The role of mathematical modeling in VOC analysis using isoprene as a prototypic example”, J. Breath Res., 5:3 (2011), 37102–37109 | DOI | MR

[34] Straub R.H., Weidler C., Demmel B., Herrmann M., Kees F., Schmidt M., Schölmerich J., Schedel J., “Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus”, Ann. Rheum. Dis., 63:8 (2004), 961–968 | DOI

[35] Hennebert O., Chalbot S., Alran S., Morfin R., “Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes”, J. Steroid Biochem. Mol. Biol., 104 (2007), 326–333 | DOI

[36] Dulos J., van der Vleuten M.A., Kavelaars A., Heijnen C.J., Boots A.M., “CYP7B expression and activity in fibroblast-like synoviocytes from patients with rheumatoid arthritis: regulation by proinflammatory cytokines”, Arthritis Rheum., 52:3 (2005), 770–778 | DOI